Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes

Diabetes Care

Volumn 34, Issue 6, 2011, Pages 1383-1388

  Ryhänen, Samppa J ^a   Härkönen, Taina ^a   Siljander, Heli ^a,b   Näntö Salonen, Kirsti ^c   Simell, Tuula ^c   Hyöty, Heikki ^b,d   Ilonen, Jorma ^c,e   Veijola, Riitta ^f   Simell, Olli ^c   Knip, Mikael ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INSULIN ANTIBODY; NEUTRAL INSULIN; PLACEBO; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; FEMALE; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

ADMINISTRATION, INTRANASAL; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DQ ANTIGENS; HUMANS; INSULIN; INSULIN ANTIBODIES; MALE; MEMBRANE GLYCOPROTEINS;

EID: 80051967777     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1449     Document Type: Article

References (21)

1. Hancock W.W., Polanski M., Zhang J., Blogg N., Weiner H.L. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol 1995;147:1193-1199
2. Daniel D., Wegmann D.R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996;93:956-960 (Pubitemid 26041202)
3. Karounos D.G., Bryson J.S., Cohen D.A. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J Clin Invest 1997;100:1344-1348 (Pubitemid 27425758)
4. Bowman M.A., Campbell L., Darrow B.L., Ellis T.M., Suresh A., Atkinson M.A. Immunological and metabolic effects of prophylactic insulin therapy in the NODscid/scid adoptive transfer model of IDDM. Diabetes 1996;45:205-208 (Pubitemid 26048674)
5. Keller R.J., Eisenbarth G.S., Jackson R.A. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993;341:927-928 (Pubitemid 23109113)
6. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
7. Skyler J.S., Krischer J.P., Wolfsdorf J., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
8. Näntö-Salonen K., Kupila A., Simell S., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. Lancet 2008;372:1746-1755
9. Achenbach P., Koczwara K., Knopff A., Naserke H., Ziegler A.G., Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114:589-597 (Pubitemid 39572109)
10. Schlosser M., Koczwara K., Kenk H., et al. In insulin-autoantibody- positive children from the general population, antibody affinity identifies those at high and low risk. Diabetologia 2005;48:1830-1832 (Pubitemid 41317837)
11. Siljander H., Härkönen T., Hermann R., et al. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev 2009;25:615-622
12. Hoppu S., Ronkainen M.S., Kimpimäki T., et al. Insulin autoantibody isotypes during the prediabetic process in young children with increased genetic risk of type 1 diabetes. Pediatr Res 2004;55:236-242 (Pubitemid 38121001)
13. Kimpimäki T., Kupila A., Hämäläinen A.M., et al. The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: The Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab 2001;86:4782-4788
14. Ilonen J., Reijonen H., Herva E., et al. Rapid HLA-DQB1 genotyping for four alleles in the assessment of risk for IDDM in the Finnish population. The Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 1996;19:795-800 (Pubitemid 26286981)
15. Nejentsev S., Sjöroos M., Soukka T., et al. Population-based genetic screening for the estimation of type 1 diabetes mellitus risk in Finland: Selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med 1999;16:985-992 (Pubitemid 30051424)
16. Sjöroos M., Iitiä A., Ilonen J., Reijonen H., Lövgren T. Triple-label hybridization assay for type-1 diabetes-related HLA alleles. Biotechniques 1995;18:870-877
17. Bottazzo G.F., Florin-Christensen A., Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279-1283
18. Williams A.J., Bingley P.J., Bonifacio E., Palmer J.P., Gale E.A. A novel micro-assay for insulin autoantibodies. J Autoimmun 1997;10:473-478 (Pubitemid 27433643)
19. Savola K., Bonifacio E., Sabbah E., et al. IA-2 antibodies - a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group. Diabetologia 1998;41:424-429 (Pubitemid 28157413)
20. Savola K., Sabbah E., Kulmala P., Vähäsalo P., Ilonen J., Knip M. Autoantibodies associated with type I diabetes mellitus persist after diagnosis in children. Diabetologia 1998;41:1293-1297 (Pubitemid 28488755)
21. Harrison L.C., Honeyman M.C., Steele C.E., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004;27:2348-2355 (Pubitemid 39281384)